Laurus Labs has received a final approval from the United States Food and Drug Administration (USFDA) for Hydroxychloroquine Tablets 200 mg.
In another development, the Company also received a tentative approval for an ANDA for ADL (Abacavir, Dolutegravir, and Lamivudine) Tablets 600 mg/50 mg/300 mg from USFDA.
The products will be commercialized from Laurus' manufacturing site located at Atchutapuram, Visakhapatnam.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
